Background Snake envenomation is a neglected global health problem. There is a need
Introduction
Snakebite envenomation is a neglected tropical and dermatologic disease. The World Health Organization estimates there are over 5 million venomous snakebites each year resulting in more than 100,000 deaths globally and more than 400,000 amputations or permanent disabilities. 1, 2 Antivenom, currently the only antidote to snake venom, is expensive, and each variant is directed against a specific species; there is no universal antivenom. Antivenom must also be administered in a hospital setting due to potential complications such as anaphylactic shock and serum sickness reactions. Victims of neurotoxic snake envenomation may not survive long enough to reach a hospital for antivenom treatment. The ideal snakebite therapy would be effective against a multitude of venoms, cheap, easy to use, portable, and able to be delivered in the field. Furthermore, though antivenom can address the systemic effects of snake venom, it may not prevent skin necrosis and local pain at the snakebite site.
We propose a dermatopharmacologic approach to treating both the local and systemic toxicity of snakebites. In this study, we repurpose a well-known dermatologic surgery technique, tumescent anesthesia, as a "contravenom" against the tissue necrosis, local pain, and systemic toxicity of snakebites. Contravenom is defined as any non-antivenom drug that treats animal envenomation.
The word tumescent is an adjective describing the state of being swollen and firm. Tumescent drug delivery refers to the subcutaneous infiltration of a relatively large volume of a dilute drug administered in a physiologic saline solution containing a low concentration of epinephrine (≤2 mg/l). A sufficient volume of a tumescent solution produces widespread subcutaneous distribution of the drug. The inclusion of epinephrine induces prolonged local vasoconstriction and delays the systemic absorption of any drug in the solution.
Tumescent lidocaine anesthesia (TLA) solution is a wellknown and commonly utilized dermatopharmacologic example of tumescent drug delivery of lidocaine (1 g/l) and epinephrine
(1 mg/l) in saline. TLA produces local anesthesia lasting for at least 10 hours with profound surgical hemostasis. 3 The delayed drug absorption permits large dosages of tumescent lidocaine (28 mg/kg) with an estimated risk for systemic toxicity of 1 per 5,000,000. 4 We hypothesize that subcutaneous tumescent epinephrine, infiltrated into and around the site of a subcutaneous lethal dose of a snake venom neurotoxin, will delay the systemic absorption of the toxin and prolong survival. Here, we establish the first animal model for tumescent drug delivery. This model was then used to test the effectiveness of tumescent drug delivery for the treatment of subcutaneous neurotoxic doses of Naja naja venom. There is a need for a prehospital snakebite treatment that is effective for a multiple snake species, safe, inexpensive, easily administered by persons having no medical training, and which is capable of prolonging survival and reducing local pain and tissue damage. Our proposed technique, "contravenom," meets the aforementioned criteria and offers a new approach for this profound global health issue.
Materials and methods
Use of the mice in this study was approved by the Institutional Animal Care and Use Committee of the University of California, Irvine. Venom Naja naja (Indian cobra) venom was obtained from Kentucky Reptile Zoo. In order to determine the median lethal dose (LD 50 ) of Naja naja venom in mice, we used an animal-sparing "up-and-down" methodology of estimating the LD 50 that involved serial intradermal injection of predetermined mg/kg dosages of venom. 6 Our estimated LD 50 value was 1 mg/kg.
Experimental procedures
Lidocaine pilot study
The pilot study used lidocaine as a model neurotoxin. Fifty-five mice were randomly selected and assigned to six treatment and control groups. Published snake venom studies using mice utilized n = 5, as such we proceeded with n ≥ 5 for the initial pilot studies. 7 All injections were given in the scruff of the neck. 
Snake venom studies
The two snake venom studies, LD 50 and LD 100 , used Naja naja venom. Mice were randomly selected and assigned to treatment and control groups. LD 100 study. Group 4 (LD 100 control): 12 mice injected subcutaneously with LD 100 dosage of venom (1 mg/kg, 0.1 ml total injection volume) in the hind leg without tumescent rescue.
Group 5 (LD 100 treatment): 12 mice injected subcutaneously with LD 100 dosage of venom (1 mg/kg, 0.1 ml total injection volume) in the hind leg. This was followed by rescue treatment at 60 seconds with tumescent epinephrine (2 ml) containing 1 mg/l epinephrine in a saline solution (0.9% NaCl) (Fig. 1 ).
Mice were monitored after venom administration every 15-60 minutes for 24 hours. An observer, blinded to treatment Surviving mice were euthanized 24 hours after venom administration. The main end-point measured was survival time.
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Statistical methods Kaplan-Meier curves were plotted for both Naja naja venom LD 50 and LD 100. Log-rank test was used to examine the difference of survival curves between control and treatment groups. Survival rate was also compared based on a twosample proportion test for venom LD 50. Median survival time was calculated for both control and treatment groups in venom LD 50. Analyses were performed using R version 3.3.3.
Results
The duration of survival was documented following subcutaneous injections of tumescent epinephrine, neurotoxic doses of lidocaine, or Naja naja cobra venom.
Lidocaine pilot study Table 1 
Naja naja studies
In Group 1 (epinephrine control), all mice survived.
LD 50 study
In Group 2 (LD 50 control), 50% of mice survived after an LD 50 dosage of Naja naja venom without tumescent epinephrine rescue. Among Group 3 (LD 50 treatment), 94% mice survived an LD 50 dosage of Naja naja venom tumescent epinephrine rescue with a 1 minute delay (P < 0.01).
LD 100 study
In Group 4 (LD 100 control), all mice died with a mean survival time of 158 minutes after an LD 100 dosage of Naja naja venom without tumescent epinephrine rescue. In Group 5 (LD 100 treatment), all mice died with a mean survival time of 230 minutes after an LD 100 dosage of Naja naja venom with tumescent epinephrine rescue at 60 seconds (P < 0.0001).
The results are displayed graphically by Kaplan-Meier survival curves in Figures 2 and 3 . The survival curve for treatment and control group under venom LD 50 were significantly different based on a Log-rank test with P = 0.0039.
For LD 50 , the percentage of mice surviving to 24 hours after venom injection was 94% (16 out of 17) in treatment group, while the survival rate in control group was only 50% (6 out of 12). The survival rate was also significantly different between two groups based on a two-sample proportion test with P = 0.0062. For LD 100, all mice died within 24 hours after venom injection for both groups. The median survival time in the control and treatment group was 158 and 230 minutes, respectively. Log-rank test indicated that survival curves were significantly different between control and treatment (P < 0.0001) (see Fig. 3 ; Table 2 ).
Discussion
The results of this research support the hypothesis that tumescent epinephrine prolongs survival of mice after lethal neurotoxic subcutaneous doses of either lidocaine or Naja naja cobra venom.
The For the Naja naja arm of this research, the tumescent contravenom solution consisted of dilute epinephrine (1 mg/l) in saline. The principal outcome variables following Naja naja envenomation were survival rate and survival duration.
After an LD 50 of Naja naja cobra venom, survival rate (number of survivors at 24 hours after envenomation) was the endpoint.
LD 50 doses of Naja naja venom followed by tumescent epinephrine resulted in a significant improvement in survival rate.
After an LD 100 dose of cobra venom, survival duration after venom injection (number of minutes survived up to 24 hours) was the endpoint. LD 100 doses of Naja naja venom resulted in uniform death of all mice, but tumescent epinephrine provided a significantly increased survival duration. 
Slow systemic absorption

Neutralizing venom in situ
Contravenom offers the possibility of neutralizing venom in situ before it has been absorbed into the systemic circulation. Snake venom contains a wide variety of toxic peptides and proteins (both enzymatic and nonenzymatic) that produce systemic neurotoxic, hemotoxic, cardiotoxic, nephrotoxic, and myotoxic effects, as well as local skin necrosis.
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Numerous drugs other than antivenom have been reported to neutralize venom in vitro. There are a number of plant-derived compounds that have been shown to neutralize snake venom in vitro. 13 Such contravenom drugs might be effective if delivered subcutaneously in a tumescent solution at the site of snakebite.
Snake venoms typically contain hyaluronidase. Adding a hyaluronidase-inhibitor to a tumescent contravenom solution might limit the extent of venom diffusion beyond the snakebite site and delay systemic absorption of venom and limit the spread of venom within local tissues. [13] [14] [15] [16] [17] [18] Venom contains cytotoxic enzymes, such as phospholipase A2 and metalloproteinases, that aid in the digestion of prey and cause tissue necrosis at the site of a snakebite. Compounds that can neutralize snake venom phospholipase A2, for example, varespladib and synthetic nanoparticles, are candidates to become contravenom drugs. 7, 19 Drugs that chelate the zinc in metalloproteinases are contravenom candidates.
Potential clinical applications
Our results suggest that human victims of a Naja naja snakebite might benefit from prompt tumescent epinephrine injection with delayed venom absorption and more time to get to hospital for antivenom therapy and life support. 
Study limitations
Our study is based on a murine model of tumescent drug delivery. Murine skin is quite lax with a thin subcutaneous fat layer.
Bulk flow of tumescent fluid in mice is quite different than in humans. A larger animal might provide a more realistic model for studying tumescent contravenom pharmacokinetics. We only focused on subcutaneous neurotoxin envenomation. 20 Our studies did not consider intramuscular envenomation. Snake venom myonecrosis is more difficult to study than neurotoxicity. Intravenous delivery of traditional antivenom may not effectively treat intramuscular envenomation. Intramuscular tumescent delivery of antivenom or contravenom ought to be studied.
Only the distal hind quarters of the mice received venom. Venom delivered to the face or neck may not respond as well to tumescent contravenom treatment. Tumescent contravenom was only given as a single dose. Repeated administrations of tumescent contravenom might also be beneficial. n/a, not applicable because there were no surviving mice in either group. a An endpoint of 1440 minutes (i.e., 24 hours) for survival was determined prior to the study. Despite the fact that some mice were expected to live >24 hours after venom injection, survival time was limited in this manner to avoid effects on reported mean survival times in surviving mice and is in accordance with commonly accepted practices for survival studies. 
